242 related articles for article (PubMed ID: 15138212)
21. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF; Vázquez Morón JM; Belvis Jiménez M; Pallarés Manrique H; Valdés Delgado T; Castro Laria L; Maldonado Pérez B; Benítez Roldán A; Perea Amarillo R; Merino V; Caunedo Álvarez Á; Argüelles Arias F
Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
25. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
26. Safety of infliximab in Crohn's disease: a large single-center experience.
Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ
Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473
[TBL] [Abstract][Full Text] [Related]
27. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
28. Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.
Alharbi O; Hamed W; Salem O; Taylor C; Besar A; Sharaf M
Saudi J Gastroenterol; 2023; 29(3):164-170. PubMed ID: 37313946
[TBL] [Abstract][Full Text] [Related]
29. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease.
Cars T; Wettermark B; Löfberg R; Eriksson I; Sundström J; Lördal M
J Crohns Colitis; 2016 May; 10(5):556-65. PubMed ID: 26733406
[TBL] [Abstract][Full Text] [Related]
30. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
31. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
Gonczi L; Vegh Z; Golovics PA; Rutka M; Gecse KB; Bor R; Farkas K; Szamosi T; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Papp M; Patai Á; Salamon Á; Tóth GT; Vincze Á; Biro E; Lovasz BD; Kurti Z; Szepes Z; Molnár T; Lakatos PL
J Crohns Colitis; 2017 Jun; 11(6):697-705. PubMed ID: 27838610
[TBL] [Abstract][Full Text] [Related]
34. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
[TBL] [Abstract][Full Text] [Related]
35. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T
Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250
[TBL] [Abstract][Full Text] [Related]
37. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
39. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
40. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]